Q&A Zealand Pharma 2019-12-03
Aktiesnakken
NOVO
TESLA
BITCOIN
Genmab
Banker og Finans
Bavarian Nordic
Amerikanske aktier
Zealand Pharma
Smallcap og First North aktier
Ennogie
Shipping
Biotek-snakken
Danske Bank
Medico
AMBU
Hansa Biopharma
Embla Medical
GN Store Nord
Gubra
Pharma
Vestas
Forsvarsaktier
Grønne Aktier
OLIE OG GAS
AI/Kunstig intelligens
EL-BILER
Maersk
|
|
3/12 18:03 af collersteen |
What has surprised you the most (positively and negatively) compared to your expectations before you took over as CEO?
|
|
|
3/12 18:05 af Emmanuel Dulac |
I am most positively surprised by the quality of Zealand's leadership team, and the highly collaborative culture of the employees. The more I work with the research team, the more I am impressed by their expertise...
|
|
|
3/12 18:08 af Emmanuel Dulac |
As for negatives (if it can be called that), there remains a lot of education around what the artificial pancreas can mean for people with insulin-dependent diabetes.
|
|
|
3/12 18:09 af Stroka |
Do you expect Zealand Pharma to be an independent company in 2025?
|
|
|
3/12 18:10 af Emmanuel Dulac |
Zealand is undergoing transformation to support sales of its own products, and we are planning to launch four products in four years starting in 2021. We have ambitious plans, industry leading competencies, and a strong financial position to realize our strategy.
|
|
3/12 18:10 af Helge Larsen/PI-redaktør |
Emmanuel Dulac..Thank You for joining us and thank you for the many fullfillinganswers to our questions. We look forward to to seeing you back here onProInvestor.com after Q4.
|
|
|
3/12 18:11 af Emmanuel Dulac |
Thank you! Thank you for the thoughtful questions. Always a pleasure to discuss with all of you.
|
|
3/12 18:11 af Helge Larsen/PI-redaktør |
This session has ended.
|
